IPVS Policy statement on safety of HPV vaccines

Papillomavirus Research

Volumn 2, Issue , 2016, Pages 9-10

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ANUS CANCER; ARTICLE; AUTOIMMUNE DISEASE; CANCER PREVENTION; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SAFETY; HEALTH CARE POLICY; MEDICAL SOCIETY; NEUROLOGIC DISEASE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; TREATMENT OUTCOME; UTERINE CERVIX CANCER; VACCINATION; VAGINA CANCER; VULVA CANCER; FEMALE; HUMAN; IMMUNOLOGY; MALE; ORGANIZATION AND MANAGEMENT; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTION; PATHOGENICITY; UTERINE CERVIX TUMOR;

COMMITTEE MEMBERSHIP; FEMALE; HUMANS; MALE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS;

EID: 85000349714     PISSN: None     EISSN: 24058521     Source Type: Journal    
DOI: 10.1016/j.pvr.2015.11.001     Document Type: Article

References (14)

1. [1] Human papillomavirus vaccines: WHO position paper, October 2014. [cited 2015 August]; Available from: 〈http://www.who.int/wer/2014/wer8943.pdf?ua=1〉.
2. [2] Global Advisory Committee on Vaccine Safety Statement on the continued safety of HPV vaccination. [cited 2015 August]; Available from: 〈http://www.who.int/vaccine_safety/committee/topics/hpv/GACVS_Statement_HPV_12_Mar_2014.pdf〉.
3. [3] Human Papillomavirus Vaccine. [cited 2015 August]; Available from: 〈http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm172678.htm〉.
4. [4] EMA to further clarify safety profile of human papillomavirus (HPV) vaccines. [cited 2015 August]; Available from: 〈http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Human_papillomavirus_vaccines/human_referral_prac_000053.jsp&mid=WC0b01ac05805c516f〉.
5. [5] Safety of HPV vaccination: A FIGO STATEMENT. [cited 2015 August ]; Available from: 〈http://www.figo.org/sites/default/files/uploads/project-publications/Statement%20on%20Safety%20of%20HPV%20vaccination%20-%20FINAL%20-%20AUGUST%202013_0.pdf〉.
6. [6] Medicines & Healthcare Products Regulatory Agency. [cited 2015 August]; Available from: 〈https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency〉.
7. [7] Gardasil (quadrivalent human papillomavirus vaccine), update 2. [cited 2015 August]; Available from: 〈https://www.tga.gov.au/alert/gardasil-quadrivalent-human-papillomavirus-vaccine-update-2〉.
8. [8] Human Papillomavirus Vaccination Coverage Among Adolescents, 2007–2013, and Postlicensure Vaccine Safety Monitoring, 2006–2014 — United States. [cited 2015 August]; Available from: 〈http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6329a3.htm?s_cid=mm6329a3_w〉.
9. [9] Human Papillomavirus (HPV) Vaccine. [cited 2015 August]; Available from: 〈http://www.cdc.gov/vaccinesafety/Vaccines/HPV/Index.html〉.
10. [10] Vichnin, M., Bonanni, P., Klein, N.P., Garland, S.M., Block, S.L., Kjaer, S.K., et al. An Overview of Quadrivalent Human Papillomavirus Vaccine Safety-2006 to 2015. Pediatr. Infect. Dis. J., 2015 Epub 2015 Jun 22.
11. [11] Arnheim-Dahlström, L., Pasternak, B., Svanström, H., Sparén, P., Hviid, A., Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study. BMJ: Br. Med. J., 2013, 347.
12. [12] Scheller, N.M., Svanström, H., Pasternak, B., Arnheim-Dahlström, L., Sundström, K., Fink, K., et al. Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system. JAMA 313:1 (2015), 54–61.
13. [13] Langer-Gould, A., Qian, L., Tartof, S.Y., Brara, S.M., Jacobsen, S.J., Beaber, B.E., et al. Vaccines and the risk of multiple sclerosis and other central nervous system demyelinating diseases. JAMA Neurol. 71:12 (2014), 1506–1513.
14. [14] International Papillomavirus Society. Available from: 〈http://www.ipvsoc.org/〉.